Glutamic Acid Decarboxylase 65, IA-2, and Insulin Autoantibodies Panel
This blood test panel measures key diabetes-related autoantibodies (GAD65, IA-2, insulin) to clarify autoimmune risk and guide next steps.
This panel bundles multiple biomarker tests in one order—your report explains how results fit together.
This is a lab panel, meaning you get multiple related antibody results from one blood draw. It focuses on three major diabetes-related autoantibodies—GAD65, IA-2, and insulin autoantibodies—to help clarify whether immune activity against the insulin-producing cells of your pancreas may be part of your glucose story.
If you are tracking A1c, fasting glucose, or fasting insulin (including while using GLP-1 medications), this panel can add a different layer of information: whether your body is making antibodies that are commonly seen in autoimmune diabetes (including adult-onset forms like LADA).
Do I need this panel?
You may consider this autoantibodies panel if your blood sugar markers and your day-to-day experience do not line up—for example, your A1c is rising despite weight loss and lifestyle changes, your glucose swings feel disproportionate to what you eat, or you need escalating medication sooner than expected.
This panel is also commonly used when you are diagnosed with diabetes as an adult but your clinical picture is “in between” type 1 and type 2—such as a leaner body type, a strong personal or family history of autoimmune disease (thyroid disease, celiac disease, vitiligo), or unexpectedly low insulin production for your stage of disease.
If you are using GLP-1 therapy (or other glucose-lowering medications) and you feel anxious about whether you are on the right plan, antibody testing can help your clinician frame whether insulin deficiency from autoimmune processes could be contributing to your results, which may change monitoring and treatment priorities.
Your results are not a diagnosis by themselves. This panel is most useful when interpreted alongside your glucose metrics (A1c, fasting glucose, continuous glucose monitor data) and insulin production markers (such as C-peptide), ideally with clinician-directed follow-up.
Autoantibody assays are method-dependent, and reference ranges can vary by lab; your report’s cutoffs and units should be used for interpretation.
Lab testing
Order this autoantibodies panel from Vitals Vault
Schedule online, results typically within about a week
Clear reporting and optional clinician context
HSA/FSA eligible where applicable
Get this panel with Vitals Vault
Vitals Vault makes it straightforward to order this lab panel and review the results in context. Because this is a bundled panel, you get a coordinated set of antibody measurements that are meant to be interpreted together, rather than as isolated numbers.
After your blood draw, you can use PocketMD to translate the pattern of results into practical next steps—what a positive antibody can mean, when it makes sense to add C-peptide or a glucose-insulin panel, and how to think about retesting if your clinical picture changes.
If you are actively adjusting therapy (including GLP-1 medications), having a clear record of your antibody status can reduce uncertainty and support more targeted conversations about monitoring frequency, hypoglycemia risk, and whether insulin deficiency may be progressing.
You can also trend your labs over time in one place, which is helpful when you are trying to reconcile an A1c that does not match your fingersticks/CGM or when you are troubleshooting plateaus and fatigue during weight loss.
- One blood draw for a coordinated antibody panel
- Results you can review alongside related metabolic labs over time
- PocketMD support for pattern-based interpretation and follow-up questions
- Designed to complement (not replace) clinician care and diagnosis
Key benefits of the Glutamic Acid Decarboxylase 65, IA-2, and Insulin Autoantibodies Panel
- Helps distinguish autoimmune diabetes patterns (including LADA) from typical insulin resistance–driven type 2 patterns.
- Clarifies whether immune activity against pancreatic beta cells may be contributing to rising glucose or medication “non-response.”
- Provides a multi-marker view, since different people express different autoantibodies at different times.
- Supports earlier, safer treatment planning when insulin deficiency is likely (for example, reducing delays in appropriate escalation).
- Adds context when A1c and daily glucose readings do not match, or when glucose variability seems out of proportion.
- Guides smart add-on testing (such as C-peptide, A1c, fasting insulin/glucose) rather than guessing what to order next.
- Creates a baseline you can reference over time, especially if symptoms, weight trajectory, or therapy changes raise new questions.
What is the Glutamic Acid Decarboxylase 65, IA-2, and Insulin Autoantibodies panel?
This lab panel measures three autoantibodies that are commonly associated with autoimmune diabetes. Autoantibodies are proteins made by your immune system that mistakenly target parts of your own body. In autoimmune diabetes, the immune system targets pancreatic beta cells, the cells that make insulin.
Because autoimmune diabetes can present in different ways—especially in adults—testing a set of antibodies is often more informative than testing only one. Some people have only one positive marker; others have multiple. The overall pattern can help estimate how likely it is that immune-mediated beta-cell damage is part of your current or future glucose regulation.
Here is what each component generally represents:
GAD65 autoantibodies (GAD65 Ab): These target glutamic acid decarboxylase, an enzyme found in beta cells and nerve tissue. GAD65 antibodies are among the most common markers in adult-onset autoimmune diabetes and can remain detectable for years.
IA-2 autoantibodies (IA-2 Ab): These target a beta-cell protein (insulinoma-associated antigen-2). IA-2 positivity is often associated with a more clearly autoimmune pattern and, in some contexts, a higher likelihood of progressing to insulin dependence.
Insulin autoantibodies (IAA): These target insulin itself. They can be seen early in autoimmune diabetes, but interpretation requires nuance because insulin antibodies can also appear after you start taking insulin injections. If you are already using insulin therapy, your clinician will interpret IAA in that context.
This panel does not measure your glucose control directly. It answers a different question: is there evidence of an autoimmune process that could explain insulin deficiency or a shift in how your diabetes behaves?
What do my panel results mean?
All antibodies negative (or below the lab cutoff)
If GAD65, IA-2, and insulin autoantibodies are all negative, it makes an autoimmune diabetes pattern less likely, but it does not completely rule it out. Autoantibodies can fluctuate, and some people with autoimmune diabetes may test negative on a limited panel or later in the disease course. In practice, an all-negative panel often shifts attention toward insulin resistance, medication effects, sleep/stress, liver fat, and lifestyle factors—while still using your glucose trends (A1c, fasting glucose, CGM) and insulin production markers (C-peptide) to confirm the bigger picture.
A clear, consistent pattern that matches your clinical picture
There is no single “optimal” antibody value the way there is for nutrients or lipids, because these markers are primarily interpreted as negative vs positive (or low-titer vs high-titer) using the lab’s reference ranges. A result pattern is most helpful when it aligns with your story: for example, if antibodies are negative and your labs show high fasting insulin with elevated triglycerides, that pattern supports insulin resistance; if one or more antibodies are positive and C-peptide is low or falling, that pattern supports autoimmune-driven insulin deficiency. The goal is a coherent explanation that guides the next right test and the safest treatment plan.
One or more antibodies positive (especially multiple positives or higher titers)
A positive result on any of these markers suggests immune activity related to pancreatic beta cells and increases the likelihood of autoimmune diabetes (including LADA in adults). Multiple positive antibodies generally strengthen that interpretation and may correlate with a higher chance of progressing toward insulin dependence over time, though the timeline varies widely. If you have positive antibodies, clinicians often pair this information with C-peptide (to assess insulin production), A1c and glucose data (to assess control), and sometimes additional autoimmune screening depending on your history. If you are already taking insulin, insulin autoantibodies can reflect treatment exposure, so the pattern across GAD65 and IA-2 becomes especially important.
Factors that influence interpretation across the panel
Several real-world factors can change how your panel is read. First, lab methods and cutoffs differ, so “borderline” results should be interpreted using your specific report and repeated if clinically indicated. Second, timing matters: antibodies may appear earlier or later, and titers can change as beta-cell function declines. Third, insulin therapy can lead to insulin antibodies, which can complicate interpretation of the insulin autoantibody line item. Finally, your overall metabolic context matters: weight loss, GLP-1 therapy, and improved insulin sensitivity can lower glucose and insulin needs, but they do not directly “treat” autoimmunity—so pairing this panel with C-peptide and glucose metrics is often the most actionable way to understand what is driving your current numbers.
What’s included in this panel
- Glutamic Acid Decarboxylase 65 Ab
- Ia-2 Antibody
- Insulin Autoantibody
Frequently Asked Questions
Do I need to fast for this autoantibodies panel?
Fasting is usually not required for autoantibody testing because the panel measures immune proteins, not glucose or lipids. If you are combining this with fasting glucose, insulin, triglycerides, or other metabolic labs, fasting may be recommended for those add-ons. Follow the instructions on your lab order.
Can this panel diagnose type 1 diabetes or LADA by itself?
No. A positive antibody result increases the likelihood of autoimmune diabetes, but diagnosis typically considers your symptoms, glucose/A1c, and insulin production (often C-peptide), plus clinical history. This panel is best viewed as evidence that helps your clinician classify your diabetes and choose the safest monitoring and treatment approach.
What if only one antibody is positive?
A single positive marker can still be meaningful, especially if it fits your clinical picture (for example, rising glucose with low or declining C-peptide). Some people express only one antibody, and different antibodies can appear at different stages. Your next step is usually to confirm the result if it is borderline and to pair it with C-peptide and glucose metrics to understand current insulin production and risk trajectory.
I’m taking insulin. Will that affect the insulin autoantibody result?
It can. Insulin antibodies may develop after exposure to injected insulin, which can make the insulin autoantibody line harder to interpret as a marker of autoimmune diabetes. In that situation, the GAD65 and IA-2 results (and your C-peptide) often carry more weight for classification.
How does this panel relate to GLP-1 medications and my A1c goals?
GLP-1 therapy can improve glucose control and reduce insulin needs by improving insulin sensitivity and slowing gastric emptying, but it does not directly determine whether autoimmunity is present. If your A1c is not improving as expected, or you are needing rapid medication escalation, antibody positivity can suggest that insulin deficiency is part of the reason. Your clinician may then focus more on C-peptide, hypoglycemia risk, and earlier insulin planning rather than only intensifying insulin-sensitizing strategies.
Should I order these antibodies separately or as a panel?
Ordering them as a panel is often more efficient because autoimmune diabetes can show up with different antibody patterns across individuals. A bundled panel reduces the chance that you miss a relevant marker and makes the results easier to interpret together as one clinical story.
What tests are commonly added if this panel is positive?
Common follow-ups include C-peptide (often with a glucose level at the same time), hemoglobin A1c, fasting glucose and fasting insulin (when appropriate), and sometimes additional autoimmune screening based on your history. If your main question is day-to-day glucose-insulin pairing, a focused panel like the Hemoglobin A1c, Insulin, and Glucose Panel can be a practical complement.